Articles tagged with Pancreatic Cancer
Researchers found a direct relationship between telomere length and pancreatic cancer risk: shorter telomeres increase the likelihood of developing the disease. The study used data from over 1,500 individuals, including those with pancreatic cancer and healthy controls, to demonstrate this link.
Research by Centre INRS–Institut Armand-Frappier and Centre de recherche du Centre hospitalier de l'Université de Montréal found a possible association between night work and increased risk of prostate, colon, lung, bladder, rectal, and pancreatic cancer. Exposure to light at night can disrupt the body's natural sleep-wake cycle.
A new study by TGen, Mayo Clinic and SHC demonstrated the power of whole genome sequencing in advancing understanding of pancreatic cancer. The research identified 142 cellular genetic coding events, including mutations, insertions and deletions, in three patients with pancreatic adenocarcinoma.
TGen's Dr. Daniel Von Hoff delivers his lecture on a molecular pursuit approach to take out pancreatic cancer, honoring the memory of patient Lori Groetken who fought the disease for two years. The award recognizes his significant contributions to genomic research and novel therapy development in pancreatic cancer.
A new study published in the American Journal of Gastroenterology found that smoking and heavy drinking can lead to an earlier onset of pancreatic cancer. The study analyzed data from 811 patients with pancreatic cancer and found that those who smoked heavily or drank excessively were diagnosed at a younger age than those who did not.
A study found that high antibody levels for Porphyromonas gingivalis were associated with a two-fold risk of pancreatic cancer, while high levels of antibodies for commensal oral bacteria were linked to a 45-percent lower risk. The study strengthens the suggestion that oral bacteria may be indicators of pancreatic cancer risk.
A Mayo-led study finds that pancreatic cancer develops from the interaction of KRAS mutations, inflammation, and epidermal growth factor receptor (EGFR), requiring multiple genetic factors for tumor formation. The study suggests that EGFR inhibitors may be effective in treating patients with chronic pancreatitis or normal p53 activity.
Researchers at Mayo Clinic found that patients without a pancreas can control their blood sugar levels as effectively as type 1 diabetes patients using insulin replacement. The study's findings suggest that removing the entire pancreas is reasonably safe and effective for diabetes management.
A new study provides a quantitative look at the experience of pancreatic cancer patients, giving them concrete data to inform their treatment decisions. The study found that maximizing quality of life is crucial for these patients, who have limited time left due to the disease.
Kansas State University researchers have made significant discoveries in cancer research by studying animal health. They found SCID pigs with severe combined immunodeficiency and discovered the connection between human cancer and pig diseases. This collaboration has huge potential for improving surgeries, drug development, and bone mar...
Research published in the journal Gut suggests that increasing dietary intake of antioxidant vitamins C, E, and selenium could cut the risk of developing pancreatic cancer. The study found a significant association between high antioxidant intake and reduced pancreatic cancer risk, with potential prevention of over one in 12 cases.
A new study published in the journal Stem Cell reveals an antibody developed by researchers can detect stem cells in organs like the liver and pancreas. This breakthrough helps understand tissue regeneration and cancer diagnosis and treatment.
A recent study found that patients who received chemotherapy following removal of periampullary cancer experienced improved overall survival compared to those who did not receive chemotherapy. The study also suggested that gemcitabine therapy provided the most significant survival benefit, with a median survival time of 43.1 months.
Researchers analyzed genes expressed in circulating tumor cells and found increased expression of WNT2, a known oncogene, in CTCs from mouse models and human patients. Targeting the WNT2 pathway may reduce metastatic potential, which is critical for controlling pancreatic cancer.
Researchers identified de novo somatic mutations in three genes associated with hemimegalencephaly, a rare childhood disease. These findings suggest potential treatments targeting the known gene mutations could reduce or prevent radical surgery.
A high-fat/calorie diet has been shown to accelerate the development of pancreatic cancer in both human epidemiological studies and mouse models. In the latter, mice fed a diet rich in fat and calories developed obesity, insulin resistance, and inflammation, all conditions that can stimulate the growth of precancerous cells.
Researchers identified a genetic marker in the vitamin D receptor gene associated with improved overall survival rates among pancreatic cancer patients. The study's findings suggest that this genetic variation may play a role in the survival of patients treated for advanced pancreatic cancer.
Researchers found that combining TH-302 with radiation reduced tumor growth in high and medium hypoxic xenografts, but not in low- or nonhypoxic implants. Tumor growth rates were also crucial in predicting treatment efficacy.
Researchers have identified leukemia inhibitory factor (LIF) as a potential target to block the growth of cancer stem cells in pancreatic tumors. Blocking LIF activity has been shown to reduce the tumor's ability to regenerate and metastasize.
A phase I study found the combination of erlotinib, bevacizumab, capecitabine, and radiotherapy to be safe and well-tolerated in patients with locally advanced pancreatic cancer. The regimen showed promising activity, with a low toxicity rate, and was associated with improved survival rates for some patients.
A recent study has identified the RLIP76 protein as a key contributor to pancreatic cancer cell resistance to chemotherapy and radiation. Depleting levels of this protein was found to kill human pancreatic cancer cells in culture and shrink established tumors in mice, making it a potential new treatment target.
Researchers found that metformin effectively eliminates cancer stem cells in pancreatic cancer, leading to tumor regression and long-term survival. Combining metformin with standard chemotherapy further eradicated both cancer stem cells and differentiated cancer cells.
Researchers found that combining GDC-0449 with standard chemotherapy improved response rates and progression-free survival for patients with advanced pancreatic cancer. The treatment targets the desmoplastic stroma and pancreatic cancer stem cells, which contribute to disease resistance.
A new study has identified elevated levels of four neurotrophic factors in a mouse model of pancreatic cancer, which could be responsible for the development of pain in patients. These findings suggest that tumor-nerve interactions play a significant role in cancer progression and pain.
A population-based study has found that high levels of ultraviolet radiation at birth, sun-sensitive skin type, and a history of skin cancer decreased the risk of pancreatic cancer. Participants born in areas with high UV radiation had a 24% lower risk compared to those born in low UV areas.
Researchers at Cardiff University have discovered a new interaction between two well-known molecules that could lead to a beneficial therapy against necrosis and inflammation in the body. The study found that blocking the effect of Bcl-2 on calcium pumps could be an attractive target for treating pancreatitis and pancreatic cancer.
A Phase 2 clinical trial is underway to test the effectiveness and safety of INNO-206 in treating advanced pancreatic ductual adenocarcinomas. The drug works like a Trojan Horse by being prepared in albumin, which pancreatic cancer cells prefer, allowing it to deliver cancer-killing agents directly to the tumor.
Researchers discovered that pancreatic cancer cells produce a protein that tricks the immune system into helping cancer growth. Blocking this protein may lead to effective treatments for pancreatic cancer. The findings suggest restoring the antitumor properties of a patient's immune system could be a therapeutic strategy.
Researchers at NYU School of Medicine have made a key discovery about the progression of pancreatic cancer, revealing how it escapes immune detection. By targeting a protein called GM-CSF, they found that immune cells can be unleashed to attack and halt tumor development.
A novel pancreatic cancer vaccine, Algenpantucel-L, has shown promising results in a Phase 2 study, improving 12-month disease-free and overall survival rates. The vaccine is designed to trigger the patient's own immune system to destroy cancer cells.
Researchers at Mayo Clinic have developed a minimally invasive technique to detect pancreatic cancer in the nearby small intestine using a light probe. The study found that this technology can detect all 10 pancreatic cancers tested, with high accuracy rates and potential for early detection without invasive procedures.
A new biomarker, PEAK1, has been identified for pancreatic cancer, a disease with low survival rates. Inhibition of PEAK1-dependent signaling sensitizes PDAC cells to existing chemotherapies.
Researchers have discovered a new class of malaria transmission-blocking compounds that work by inhibiting bumped kinase I, blocking the parasite's infectious stage. Genetic variation is also linked to high blood pressure, with researchers finding that inhibiting renin pathway activity can return blood pressure to normal levels.
Researchers at Dana-Farber Cancer Institute discovered that advanced pancreatic cancers in mice cannot survive without the mutant Kras oncogene, which rewires key metabolic pathways. The study suggests that targeting these altered metabolic pathways might be a potential approach to treat the deadly cancer.
Researchers discovered that mutant Kras manipulates metabolic pathways to support tumor growth and progression in pancreatic cancer. The study found that turning off the oncogene caused tumors to regress and metabolic changes correlated with gene expression changes.
A Mayo Clinic study found that the dietary supplement gamma-linoleic acid can inhibit the growth of a subset of pancreatic cancer cells and selectively promote cancer cell death in mice. Combining GLA with chemotherapy drug gemcitabine significantly inhibited tumor growth.
Researchers found that over 40% of high-risk individuals have detectable pancreatic lesions, which increase with age. Endoscopic ultrasound is more effective than MRI and CT scans in detecting these lesions. Early detection can help prevent the disease by removing precancerous lesions.
A first-of-its-kind clinical trial demonstrated the feasibility of selecting treatment based on individual molecular characteristics in advanced pancreatic cancer. The study found that biopsies could be safely conducted and multiple drug targets identified, suggesting potential benefits for some patients.
Researchers have developed a method to destroy cancer cells using the death cap mushroom's α-amanitin toxin without harming healthy cells. The toxin is linked to an antibody that targets a protein on cancer cells, inhibiting tumor growth and causing regression in mice.
A Mayo Clinic-led study has found that a combination of the novel drug TH-302 with standard drug gemcitabine delays cancer worsening in patients with advanced pancreatic cancer. The 2-drug combo showed a 5.6-month progression-free survival, significantly extending the average survival of six to seven months.
A new study published by the American College of Surgeons found that patients who underwent an operation as part of their cancer treatment and started a regular walking regimen experienced less fatigue than those who did not. After three months, the intervention group reported a 27% improvement in fatigue, compared to a 19% improvement...
A Johns Hopkins study of thousands of identical twins found that whole genome sequencing is not informative for predicting most common diseases. While the test can alert individuals to an increased risk of certain diseases, it fails to forewarn them of others they may ultimately develop.
Scientists at Fox Chase Cancer Center have discovered compounds that enhance the effects of gemcitabine, improving its ability to kill pancreatic cancer cells. This breakthrough could lead to a lower dose of chemotherapy with fewer side effects, potentially increasing survival rates for patients.
Researchers at Fox Chase Cancer Center found that survivin levels were associated with longer disease-free survival and better response to chemotherapy in patients with pancreatic cancer. The study suggests that survivin could be a useful tool for identifying patients who may benefit from specific treatments.
Researchers found success with irreversible electroporation to treat primary and metastatic liver cancer; the technique is now being implemented as a treatment for pancreatic cancer. Two out of eight participants had successful resections after IRE, with improved survival rates compared to traditional treatments.
Researchers have identified a new protein, S100PBP, that suppresses cathepsin Z and reduces pancreatic cancer cells' ability to attach to other tissues. This discovery may lead to the development of novel preventive and therapeutic targets for pancreatic cancer.
Scientists at Fred Hutchinson Cancer Research Center and TGen have discovered a way to break down the biological barrier surrounding pancreatic cancer tumors, allowing chemotherapy drugs to reach the cancerous tissue. This breakthrough could lead to improved survival rates for patients with pancreatic cancer.
Researchers at Fred Hutchinson Cancer Center have discovered a way to break down the biological barrier surrounding pancreas cancer tumors, allowing chemotherapy to penetrate and increase survival rates. The new approach shows significant promise for treating this deadly disease.
The Pancreatic Cancer Action Network and AACR have awarded $1.2 million in grants to two postdoctoral fellows, Stephanie K. Dougan and Oliver G. McDonald, to advance pancreatic cancer research through immunotherapy and epigenetic reprogramming studies.
A phase I clinical trial of patients with advanced pancreatic cancer showed promise with rigosertib, achieving stable disease in 11 of 19 patients for a median duration of 113 days. The drug targets PLK1 and PI3K signals that allow cancer cells to divide rapidly.
Researchers have found that combining gemcitabine with nab-paclitaxel increases intratumoral gemcitabine levels by reducing the primary metabolizing enzyme, cytidine deaminase. This combination may lead to improved patient outcomes and better administration of therapeutic treatments.
Breast cancer death rates are declining across the EU, with a predicted drop of 9% for women and 13% among young women. Pancreatic cancer deaths are rising, but overall cancer mortality rates are falling due to advancements in treatment and prevention.
The 9th annual Seena Magowitz Celebrity Golf Classic raised funds for pancreatic cancer research at the Translational Genomics Research Institute (TGen). The event supported new international clinical trials and initiatives against pancreatic cancer.
A mutant protein in nearly all pancreatic cancers plays a role in its development and continued growth, according to a U-M study. Inactivating Kras eliminated tumors in mice, but left fibrous areas similar to scar tissue, suggesting possible treatment targets.
Researchers at the Translational Genomics Research Institute and University of Arizona have received a grant to study targeted cancer therapies for pancreatic cancer, which shows promise in reducing side effects. The center aims to develop novel antitumor agents that can extend the productive lives of patients with cancer.
Researchers identified a molecular loop between mutated Kras, NF-κB, and IL-1α, which perpetuates inflammation, tumor growth, and poor survival in pancreatic cancer. This discovery suggests targeting IL-1α as a potential treatment avenue to block the elusive target of mutated Kras.
Researchers at the University of Pennsylvania School of Medicine have discovered that pancreatic cancer cells in an animal model begin to spread before clinically obvious tumor tissue is detected. Inflammation plays a crucial role in enhancing cancer progression, leading to the entry of cancer cells into the bloodstream. The study used...
Researchers have made significant progress in detecting and treating gastrointestinal cancers with new biomarkers, test, and treatments. Studies show promising results for detecting early stage pancreatic cancer and improving survival in patients with metastatic colorectal cancer.
A team of researchers identified genetic mutations in OATP1B1 and OATP1B3 as the cause of Rotor syndrome, a rare genetic disorder characterized by jaundice. Complete deficiency of these proteins causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.
A Stanford study found that a well-known protein complex controls DNA expression and prevents pancreatic cancer. The researchers discovered genetic changes in the protein complex were present in nearly a third of human pancreatic cancers, suggesting its role in tumor suppression.